Breast Cancer Coverage from Every Angle
Editor:
William J. Gradishar, MD, FACP, FASCO
Advertisement
Advertisement

News

Could Adjuvant Tamoxifen Reduce Breast Cancer Recurrence for Some Patients Who Forgo Radiation?
Imlunestrant Alone and Combined With Abemaciclib in Advanced Breast Cancer
Primary Prevention of Breast Cancer Based on AI Risk Model
Endocrine vs Radiation Therapy: Quality of Life for Older Patients With Breast Cancer
T-DXd Receives FDA Approval for Treatment of Select Patients With Metastatic Breast Cancer
Dato-DXd Approved by FDA for HR-Positive, HER2-Negative Breast Cancer
Does Adding Palbociclib to Combination Therapy Improve Outcomes in Metastatic Breast Cancer?
Can Some Patients Avoid Chest Wall Irradiation After Mastectomy?
Is Active Monitoring a Viable Treatment Option for Some Patients With Low-Risk DCIS?
SABCS 2024: Risk-Reducing Surgery in BRCA Carriers With Early-Onset Breast Cancer?
SABCS 2024: Margetuximab vs Trastuzumab Combinations in Early HER2-Positive Breast Cancer
SABCS 2024: Correlation of Biomarkers With Outcomes in Early Triple-Negative Breast Cancer
SABCS 2024: PADMA Compares First-Line Treatments in High-Risk Metastatic Breast Cancer
SABCS 2024: T-DXd vs Chemotherapy in Previously Treated Metastatic Breast Cancer
SABCS 2024: HER3-DXd Under Study in HR-Positive, HER2-Negative Early Breast Cancer
Changes in Reproductive Patterns Across Generations in Caribbean Patients With Breast Cancer
Is Intrauterine Hormonal Contraception Associated With Increased Breast Cancer Risk?
SITC 2024: Elucidating the Therapeutically Relevant Mechanisms of TROP2 in Breast Cancer
SITC 2024: Adding IL-4 Inhibitor to PD-1 Inhibitor Therapy for ER-Positive Breast Cancer
SITC 2024: CRISPR Editing Yields New B-Cell Strategies for Treating HER2-Positive Breast Cancer
SITC 2024: Wnt Inhibitor Emerges as Regulator of Breast Cancer Progression
SITC 2024: Overcoming PARP Inhibitor Resistance in BRCA1-Mutated Breast Cancer
Novel CKD4/6 Inhibitor Under Study in Advanced Breast Cancer
Radiotherapy Strategy for Enhancing Immunotherapy for Triple-Negative Breast Cancer
Ivonescimab Plus Chemotherapy for Triple-Negative Breast Cancer
Lymphedema and Hypofractionated Nodal Regional Irradiation
Abemaciclib Plus Endocrine Therapy Under Study in Advanced Breast Cancer
Novel CDK2/4 Inhibitor Under Study in Metastatic Breast Cancer
Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.